多发性硬化症患者的血清奥克雷利祖马布度:从常规医疗保健中进行的横截面研究
Moskorova Denisa1, Kacirova Ivana1, Hradilek Pavel2
1Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 703 00, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, Ostrava 708 52, Czech Republic.
Multiple sclerosis and related disorders
|June 26, 2025
概括
在多发性硬化症患者中,血清ocrelizumab度的差异很大. 身体大小和剂量后的时间等因素会影响这些水平,可能会影响治疗的有效性和毒性风险.
科学领域:
- 药理动力学 药理动力学
- 免疫学 免疫学 免疫学
- 神经学 神经学
背景情况:
- 奥克雷利祖马布是一种治疗多发性硬化症 (MS) 的单克隆抗体.
- 在MS患者中测量了常规血清ocrelizumab度.
- 使用了超高性能液态色谱学-双重质谱学.
研究的目的:
- 测量MS患者的血清奥克雷利祖马布度.
- 为了研究影响ocrelizumab水平的因素.
- 为了评估ocrelizumab药理动学的变异性.
主要方法:
- 研究了180名接受300毫克或600毫克ocrelizumab的MS患者.
- 根据血液采集时间 (≤28周与>28周) 划分患者.
- 分析了血清奥克雷利祖马布,血细胞和免疫球蛋白 (A,G,M).
主要成果:
- 根据剂量 (300 mg与600 mg) 的不同,ocrelizumab度有显著的变化.
- 在ocrelizumab水平与体重,身高,BSA和BMI之间发现了反向相关性.
- 较晚剂量后 (>28周) 和某些血液学/免疫球蛋白参数观察到较低度.
结论:
- 血清中ocrelizumab度的显著个体间变异被观察到.
- 这种受患者因素影响的药物动力学变化可能会增加毒性或低于最佳治疗的风险.
- 了解可变性对于优化MS中ocrelizumab治疗至关重要.
相关概念视频
Clinical Trials
8.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.7K
Drug Concentrations: Measurements
617
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
617
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Pharmacovigilance
1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Enzyme-Linked Immunosorbent Assay
14.2K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
14.2K
Prevalence and Incidence
833
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
833


